Government of Canada purchases avian influenza vaccine to protect individuals most at risk

The Public Health Agency of Canada (PHAC) and its partners are focused on keeping people and animals in Canada safe and ensuring Canada is ready for any potential health threats. This includes taking proactive measures to protect the health of people in Canada by authorizing and securing the supply of a human vaccine against avian influenza as part of our readiness and potential use, as needed, based on risk conditions. Leveraging an existing agreement, PHAC has secured an initial supply of 500,000 doses of GSK’s human vaccine against avian influenza – ArepanrixTM H5N1 A/American wigeon clade 2.3.4.4b. This vaccine will be used as part of Canada’s contingency planning to protect people who may be at increased risk of being exposed to the virus through animals infected with avian influenza.